Search results for " ASTHMA"

showing 10 items of 300 documents

Assessing and accessing the small airways; implications for asthma management

2013

Despite the wealth of experience in the management of asthma, the disease remains inadequately controlled in some patients, who face long-term respiratory impairment and disability. The disease has been characterised as an inflammatory condition affecting first the larger airways and eventually the smaller airways, but there is evidence that peripheral airway involvement defines a particular and more severe phenotype of asthma. For this reason, assessing functional and biological parameters reflective of small airways involvement is important prognostically. No assessment method is universally and directly representative of peripheral airway function, but the traditional spirometric tests, …

Pulmonary and Respiratory Medicinemedicine.medical_specialtyVital capacityVital CapacityDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioAsthma managementAir trappingNitric OxideNitric Oxide; Respiratory Function Tests; Vital Capacity; Humans; Tomography X-Ray Computed; Asthma; Forced Expiratory Volume; Breath TestsForced Expiratory VolumeMedicineHumansPharmacology (medical)Intensive care medicineAsthmaRespiratory Function Testbusiness.industrySmall airwaysBiochemistry (medical)medicine.diseaseResponse to treatmentAsthmarespiratory tract diseasesRespiratory Function TestsImpulse OscillometryBreath TestsAnesthesiamedicine.symptombusinessTomography X-Ray ComputedHuman
researchProduct

The Burden of Rhinitis and Rhinoconjunctivitis in Adolescents

2014

Purpose Rhinitis and conjunctivitis are common diseases worldwide that are frequently associated. Nevertheless, the risk factors for rhinoconjunctivitis are not well-described and the impact of conjunctivitis on rhinitis and asthma in children remains unknown. This study explored the different risk factors and evaluated the burden of rhinoconjunctivitis among adolescents. Methods This was a cross-sectional study conducted on a random sample of schoolchildren, aged 10-17 years, using skin prick tests and a self-administered questionnaire on respiratory health investigating the impact of rhinitis and rhinoconjunctivitis on daily activities. Results A complete evaluation was obtained for 2,150…

Pulmonary and Respiratory Medicinemedicine.medical_specialtybusiness.industryRhinitis conjunctivitis epidemiology asthma childrenImmunologyRespiratory Hypersensitivityasthmamedicine.diseaseDermatologyDisease coursechildrenImmunologyEpidemiologymedicineconjunctivitisImmunology and AllergyOriginal ArticleepidemiologybusinessAsthmaRhinitis
researchProduct

Indacaterol/glycopyrronium/mometasone fixed dose combination for uncontrolled asthma

2021

INTRODUCTION Asthma symptoms can be relieved through a maintenance treatment combining long-acting β2-agonist and inhaled corticosteroids (LABA/ICS). However, for patients with inadequately controlled asthma, the LABA/ICS combination might not be sufficient. Under these conditions, clinical guidelines recommend the administration of inhaled long-acting muscarinic antagonists (LAMA) as an add-on therapy to LABA/ICS to better control asthma and improve lung function. For nearly two decades, the only LAMA to be approved on the market has been tiotropium. AREAS COVERED We reviewed recent clinical studies evaluating the safety and efficacy of LABA/LAMA/ICS fixed dose combinations by searching Pu…

Pulmonary and Respiratory Medicinemedicine.medical_specialtycorticosteroidFixed-dose combinationLABAAsthma corticosteroid fixed dose combination ICS inhaler LABA LAMA once daily combination uncontrolled asthmaMuscarinic Antagonistsonce daily combinationQuinolonesSettore MED/10 - Malattie Dell'Apparato RespiratorioinhalerAdrenal Cortex HormonesInternal medicineAdministration InhalationImmunology and AllergyMedicineHumansfixed dose combinationAdrenergic beta-2 Receptor AgonistsAsthmaFluticasonebiologyInhalationuncontrolled asthmabusiness.industryInhalerPublic Health Environmental and Occupational HealthLAMALamamedicine.diseasebiology.organism_classificationGlycopyrrolateFluticasone-Salmeterol Drug CombinationAsthmarespiratory tract diseasesDrug CombinationsICSIndansIndacaterolSalmeterolbusinessMometasone Furoatehormones hormone substitutes and hormone antagonistsmedicine.drug
researchProduct

BMI can influence adult males' and females' airway hyperresponsiveness differently

2012

Abstract Background Epidemiological data indicate that obesity is a risk factor for asthma, but scientific literature is still debating the association between changes in body mass index (BMI) and airway hyperresponsiveness (AHR). Methods This study aimed at evaluating the influence of BMI on AHR, in outpatients with symptoms suggestive of asthma. 4,217 consecutive adult subjects (2,439 M; mean age: 38.2±14.9 yrs; median FEV1 % predicted: 100 [IQR:91.88-107.97] and FEV1/FVC % predicted: 85.77% [IQR:81.1-90.05]), performed a methacholine challenge test for suspected asthma. Subjects with PD20 20 20 > 800 were considered affected by severe, moderate or mild AHR, respectively. Results A total …

Pulmonary and Respiratory Medicineobesitymedicine.medical_specialtyPathologyAirway hyperresponsivenessPhysiologybody mass indexSettore MED/10 - Malattie Dell'Apparato Respiratorio03 medical and health sciencesFEV1/FVC ratio0302 clinical medicineAirway hyperresponsivenessEpidemiologymedicinemales and femalesobesity hyperreactivity lung function genderOriginal Research Article030212 general & internal medicineRisk factorSuspected asthmaAsthmalcsh:RC705-7792. Zero hungerbusiness.industrymethacholine testlcsh:Diseases of the respiratory systemasthmarespiratory systemmedicine.diseaseObesityrespiratory tract diseases030228 respiratory systembusinessBody mass index
researchProduct

ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy

2021

Funding Information: BSreports personal fees from Allergopharma, during the conduct of the study; grants from National Health Programm, grant, personal fees from Polpharma, ASTRA, personal fees from Mylan, Adamed, patient ombudsman, national Centre for Research and Development, Polish Allergology Society. Funding Information: NGP reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from Gerolymatos International SA, Capricare. Funding Information: CA reports grants from Allergopharma, grants from Idorsia, Swiss National Science Foundation, Christine Kühne‐Center for Allergy Rese…

Pulmonary and Respiratory Medicineprecision medicineeducationImmunology610ReviewSettore MED/10 - Malattie Dell'Apparato Respiratorioimmune system diseasesHDE ALERallergic rhinitis ; asthma ; immunotherapy ; precision medicineMedicine and Health SciencesImmunology and Allergy[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/AllergologyComputingMilieux_MISCELLANEOUSRhinitisallergic rhinitisallergic rhinitis; asthma; immunotherapy; precision medicineasthmaRC581-607respiratory tract diseases3121 General medicine internal medicine and other clinical medicineimmunotherapyImmunologic diseases. Allergy600 Technik Medizin angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit[SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergologyallergic rhinitis asthma immunotherapy precision medicine
researchProduct

Severe asthma and COVID-19: lessons from the first wave

2020

Objective: Severe asthma is considered a risk factor for SARS-Coronavirus 2 (SARS-CoV-2) infection but scientific evidences are lacking. Methods: we performed a literature search and review based on PubMed database national, international recommendations as well as papers on severe asthmatic patients and their management during SARS-CoV-2 pandemic. Results: the majority of international recommendations, expert panels and editorials provide indications about management of severe asthmatic patients. No published studies evaluated the effects of biologic agents on severe asthmatic patients during SARS-CoV-2 pandemic. Conclusions: the relationship between SARS-CoV-2 and asthma is variable world…

Pulmonary and Respiratory Medicinesevere asthma2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)biologic agentsvirusesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Severe asthmaInhaled corticosteroidsSettore MED/10 - Malattie Dell'Apparato Respiratoriooral corticosteroids03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinemedicineHumansImmunology and AllergyAnti-Asthmatic AgentsPediatrics Perinatology and Child Health030212 general & internal medicineRisk factorskin and connective tissue diseasesPandemicsAsthmabusiness.industryAsthma; biologic agents; COVID-19; inhaled corticosteroids; oral corticosteroids; SARS-CoV-2; severe asthmaSARS-CoV-2fungiPatient AcuityAsthma biologic agents COVID-19 inhaled corticosteroids oral corticosteroids SARS-CoV-2 severe asthmaCOVID-19medicine.diseaseAsthmarespiratory tract diseasesBiologic Agentsbody regions030228 respiratory systemPractice Guidelines as TopicPediatrics Perinatology and Child Healthinhaled corticosteroidsbusiness
researchProduct

Overcoming Barriers to the Effective Management of Severe Asthma in Italy.

2021

Pierluigi Paggiaro,1 Simona Barbaglia,2 Stefano Centanni,3,4 Davide Croce,5 Enrico Desideri,6 Saffi Giustini,7,8 Claudio Micheletto,9 Antonino Musarra,10 Nicola Scichilone,11 Ugo Trama,12 Maria Teresa Zedda,7,13 Giorgio Walter Canonica14 1Department of Surgery, Medicine, Molecular Biology, and Critical Care, University of Pisa, Pisa, Italy; 2Associazione Nazionale Pazienti “Respiriamo Insieme”, Padova, Italy; 3Department of Health Sciences, Università degli Studi di Milano, Milan, Italy; 4Respiratory Unit, ASST Santi Paolo e Carlo, Milan, Italy; 5Center for Health Economics, Social and Health Care Management, LIUC-Università Cattaneo, Castellanza, I…

Pulmonary and Respiratory Medicinesevere asthmaReferralunmet needsSettore MED/10 - Malattie Dell'Apparato Respiratoriooral corticosteroids03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Biologic therapy Expert opinion Oral corticosteroids Severe asthma Unmet needsMultidisciplinary approachHealth careJournal of Asthma and AllergyImmunology and AllergyMedicine0601 history and archaeologybiologic therapyInformation exchange060102 archaeologybusiness.industryMedical record06 humanities and the artsRC581-607medicine.diseaseExpert OpinionIntegrated care030228 respiratory systemMedical emergencyImmunologic diseases. AllergybusinessPatient educationJournal of asthma and allergy
researchProduct

Onset of Effect, Changes in Airflow Obstruction and Lung Volume, and Health-Related Quality of Life Improvements with Benralizumab for Patients with …

2020

Reynold A Panettieri Jr,1 Tobias Welte,2 Kartik V Shenoy,3 Stephanie Korn,4 Margret Jandl,5 Edward M Kerwin,6 Rosa Feijoo,7 Peter Barker,8 Richard F Olsson,9 Ubaldo J Martin8 On behalf of the SOLANA Study Investigators1Pulmonary, Allergy and Critical Care Division, University of Pennsylvania, Philadelphia, PA, USA; 2Department of Respiratory Medicine, Member of the German Center of Lung Research, Medizinische Hochschule Hannover, Hannover, Germany; 3Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA; 4Pulmonary Department, Universitätsmedizin Mainz, Langenbeckstr, Mainz, Germany; 5Hamburger Institut Für Th…

Pulmonary and Respiratory Medicinesevere asthmamedicine.medical_specialtybenralizumabPlacebolaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicineClinical endpointJournal of Asthma and AllergyImmunology and AllergyMedicinePlethysmographLung volumesOriginal Researchbusiness.industryBenralizumabanti–IL-5RαConfidence intervalchemistryAsthma Control Questionnairerandomized controlled trialinterleukin-5businesseosinophilicJournal of Asthma and Allergy
researchProduct

Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma.

2021

Objective: This study analysed whether the persistence of both reversible airway obstruction (RAO) and elevated BE counts was associated to reduced asthma control and accelerated lung function decline in treated severe asthmatics. Methods: About 202 severe asthmatics were studied after 12–120 months of step-5 treatment associated to anti-IgE therapy. Following treatments, reversibility tests, after inhaling 400 mcg of Salbutamol, were performed. FEV1 > 12% or ≤12% changes differentiated RAO+ from RAO− subjects. Blood eosinophil (BE) counts after treatment were considered. Results: Pre-/post-treatment bronchodilator FEV1% and ACT were lower (61% [50–71], 74.4% [62.5–83.7] and 20[18–22]), …

Pulmonary and Respiratory Medicinesevere asthmamedicine.medical_specialtymedicine.drug_classSevere asthmaEosinophilSettore MED/10 - Malattie Dell'Apparato RespiratorioGastroenterologyPersistence (computer science)03 medical and health sciences0302 clinical medicineInternal medicineBronchodilatorallergic asthma blood eosinophil bronchodilator reversibility lung function decline severe asthma salbutamolForced Expiratory VolumemedicineSettore MED/10Immunology and AllergyHumans030212 general & internal medicineBlood eosinophilLungGenetics (clinical)Lung functionBronchodilator Agentallergic asthma; blood eosinophil; bronchodilator reversibility; lung function decline; severe asthma; salbutamol; bronchodilator agents; eosinophils; forced expiratory volume; humans; lung; airway obstruction; asthmabusiness.industrylung function declineAirway obstructionmedicine.diseaseAsthmaBronchodilator AgentsAirway ObstructionEosinophilsbronchodilator reversibility030228 respiratory systemsalbutamolSalbutamolBlood eosinophilsbusinessallergic asthmamedicine.drugHumanblood eosinophilThe clinical respiratory journalREFERENCES
researchProduct

Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B…

2016

Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) focuses on the integrated care of chronic diseases. Area 5 (Care Pathways) was initiated using chronic respiratory diseases as a model. The chronic respiratory disease action plan includes (1) AIRWAYS integrated care pathways (ICPs), (2) the joint initiative between the Reference site MACVIA-LR (Contre les MAladies Chroniques pour un VIeillissement Actif) and ARIA (Allergic Rhinitis and its Impact on Asthma), (3) Commitments for Action to the European Innovation Partnership on Active and Healthy Ageing and the AIRWAYS ICPs network. It is deployed in collaboration with the World Health Organizatio…

Pulmons -- Malalties obstructivesVeterinary medicineAllergyPublished ErratumLANGUEDOC-ROUSSILLONAllergyRespiratory Medicine and Allergy[SDV]Life Sciences [q-bio]Aparell respiratori -- MalaltiesOPERATIONAL DEFINITIONAlternative medicineReviewChronic respiratory diseasesGLOBAL ALLIANCESYSTEMS MEDICINE0302 clinical medicineMedicine and Health SciencesImmunology and AllergyMACVIA030212 general & internal medicineAIRWAYS ICPLungmedicin och allergiEIP on AHA; European Innovation Partnership on Active and Healthy Ageing; Chronic respiratory diseases; AIRWAYS ICPs; MACVIA; ARIA; Scaling upGINA STRATEGYAIRWAYSUPDATE ARIA 2008Scaling upRespiratory disease:Outras Ciências Agrárias [Ciências Agrárias]3. Good healthChronic respiratory diseaseALLERGIC RHINITISICPsAIRWAYS ICPsGeneral partnershipAction planErratumLife Sciences & BiomedicineAIRWAYS ICPs; ARIA; Chronic respiratory diseases; EIP on AHA; European Innovation Partnership on Active and Healthy Ageing; MACVIA; Scaling upPulmonary and Respiratory Medicinemedicine.medical_specialtyEIP on AHAAIRWAYS ICPs; ARIA; Chronic respiratory diseases; EIP on AHA; European Innovation Partnership on Active and Healthy Ageing; MACVIA; Scaling up; Immunology and AllergyEmerging technologiesImmunologyREFERENCE SITESocio-culturalePredictive medicine03 medical and health sciencesEuropean Innovation Partnership on Active and Healthy AgeingNursingCritical success factorJournal Articlemedicineddc:610Science & TechnologyARIAbusiness.industrySettore MED/09 - MEDICINA INTERNAAIRWAYS-ICPSmedicine.diseaseIntegrated careAlliance030228 respiratory systemCiências Agrárias::Outras Ciências Agrárias3121 General medicine internal medicine and other clinical medicineFamily medicineImmunologyHealthy ageingbusinessSEVERE ASTHMA
researchProduct